Dakota Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Dakota Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,200	Closed	-$224K	–	806
2025 Q3	$224K	Sell	3,200 -1,701	-35%	-$115K	﹤0.01%	607
2025 Q2	$314K	Sell	4,901 -3,069	-39%	-$190K	0.01%	602
2025 Q1	$506K	Sell	7,970 -1,100	-12%	-$74K	0.01%	507
2024 Q4	$603K	Sell	9,070 -200	-2%	-$13.8K	0.01%	470
2024 Q3	$647K	Sell	9,270 -1,200	-11%	-$83.1K	0.01%	459
2024 Q2	$679K	Hold	10,470	–	–	0.02%	449
2024 Q1	$678K	Hold	10,470	–	–	0.02%	448
2023 Q4	$689K	Sell	10,470 -1,810	-15%	-$105K	0.03%	375
2023 Q3	$700K	Buy	12,280 +250	+2%	+$15.2K	0.03%	341
2023 Q2	$737K	Sell	12,030 -600	-5%	-$37.4K	0.03%	304
2023 Q1	$793K	Sell	12,630 -250	-2%	-$16.1K	0.05%	270
2022 Q4	$818K	Hold	12,880	–	–	0.06%	253
2022 Q3	$759K	Buy	+12,880	New	+$794K	0.06%	256

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Dakota Wealth Management's PBE Position: Q4 2025 in Review

Dakota Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2025, closing a stake of 3,200 shares — an estimated $224K sold.

Dakota Wealth Management first reported a position in PBE in Q3 2022 and held it in 13 quarters. The position peaked at $818K in Q4 2022. 108 funds tracked by Wall St. Rank hold PBE as of Q4 2025.

Dakota Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2025 after selling out during the quarter.
Dakota Wealth Management sold 3,200 Invesco Biotechnology & Genome ETF shares in Q4 2025, an estimated $224K.
Dakota Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q3 2022 and held it in 13 quarters.
Dakota Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $818K in Q4 2022.
108 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2025.

Based on Dakota Wealth Management's 13F filing for Q4 2025, filed 13 Jan 2026.